<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574130</url>
  </required_header>
  <id_info>
    <org_study_id>MTU-EC-IM-2-046/57</org_study_id>
    <nct_id>NCT02574130</nct_id>
  </id_info>
  <brief_title>Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria</brief_title>
  <official_title>Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thammasat University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thammasat University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the cure rate from ventilator-associated pneumonia
      (VAP) caused by Gram negative bacteria when administering add on nebulized amikacin to
      intravenous antibiotics compared to intravenous antibiotics alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After inclusion, the patients are randomized into two groups: nebulized amikacin plus
      intravenous antibiotic(s) or nebulized placebo plus intravenous antibiotic(s). The dose of
      nebulized amikacin is 400 mg every 12 hours for 10 days. The patients are followed up on day
      3, 7, 10, and 28 for safety and efficacy. The estimate sample size is 84 subjects base on
      previous study of cure rate in VAP and the authors expected that nebulized amikacin can
      improve cure rate in VAP subjects for 30% when compared with intravenous antibiotic(s) alone
      with power of 80% at level of significance 0.05.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cure rate</measure>
    <time_frame>10 days after end of the intervention</time_frame>
    <description>Cure rate = improvement/ no new infiltration of chest radiography plus 2/3 of the following: 1) No fever within 48 hours after end of the intervention 2) The reduction of secretion 3) The reduction of white blood cell</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The reduction of pathogens</measure>
    <time_frame>10 days after end of the intervention</time_frame>
    <description>quantitative sputum cultures were measured every days for 10 days or no growth of organism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
    <time_frame>at 28 days after end of the intervention</time_frame>
    <description>All causes of death during the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of mechanical ventilation</measure>
    <time_frame>at 28 days after end of the intervention</time_frame>
    <description>number of days on mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of ICU stay</measure>
    <time_frame>at 28 days after end of the intervention</time_frame>
    <description>number of ICU days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospitalization</measure>
    <time_frame>at 28 days after end of the intervention</time_frame>
    <description>number of days hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of intervention drug</measure>
    <time_frame>at 28 days after end of the intervention</time_frame>
    <description>Any adverse events were recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pneumonia, Ventilator-Associated</condition>
  <arm_group>
    <arm_group_label>Nebulized amikacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amikacin 400 mg nebulized every 12 hours plus intravenous antibiotic(s) for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>nebulized placebo every 12 hours plus intravenous antibiotic(s)for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amikacin</intervention_name>
    <description>400 mg, nebulizer, every 12 hours, 10 days</description>
    <arm_group_label>Nebulized amikacin</arm_group_label>
    <other_name>Amikin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo 4 ml, nebulizer, every 12 hours, 10 days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18 years

          -  On mechanical ventilator more than 7 days

          -  VAP diagnosis inclusion criteria:

               1. new/progressive infiltration of chest radiography

               2. 2/3 of the following: 1) fever 2) purulent sputum 3) Wbc &gt; 12,000 cell/mm3 or &lt;
                  4,000 cell/mm3

          -  Evidence of gram negative bacilli from sputum gram stain or previous sputum culture
             within 1 week

        Exclusion Criteria:

          -  History of amikacin allergy

          -  GFR &lt; 30 mL/min except dialytic patients

          -  Immunocompromised host: HIV CD4 &lt; 200 cells/mm3, leukemia, lymphoma, received
             chemotherapy within 3 weeks, Absolute neutrophil count &lt; 500/mm3

          -  Severe ARDS (P/F ratio &lt; 100)

          -  Endobronchial obstruction:endobronchial mass, endobronchial stenosis

          -  Atelectasis

          -  Severe bronchospasm

          -  Lung abscess

          -  Complicated parapneumonic effusion/ Empyema

          -  Chest trauma

          -  Uncontrolled extrapulmonary infection(s)

          -  Received intravenous antibiotic(s) more than 48 hours

          -  Pregnancy/ Lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pitchayapa Ruchiwit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thammasat university hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thammasat University (Rangsit center)</name>
      <address>
        <city>Pathumthani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/19698010</url>
    <description>Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed?term=Eur.+J.+Clin.+Microbiol.+Infect.+Dis%5BJour%5D+AND+Ghannam+DE%5Bauthor%5D&amp;cmd=detailssearch</url>
    <description>Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance</description>
  </link>
  <results_reference>
    <citation>Czosnowski QA, Wood GC, Magnotti LJ, Croce MA, Swanson JM, Boucher BA, Fabian TC. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy. 2009 Sep;29(9):1054-60. doi: 10.1592/phco.29.9.1054.</citation>
    <PMID>19698010</PMID>
  </results_reference>
  <results_reference>
    <citation>Ghannam DE, Rodriguez GH, Raad II, Safdar A. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis. 2009 Mar;28(3):253-9. doi: 10.1007/s10096-008-0620-5. Epub 2008 Aug 28.</citation>
    <PMID>18752007</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thammasat University</investigator_affiliation>
    <investigator_full_name>Pitchayapa Ruchiwit</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

